Trump signs executive order accelerating research into psychedelic drug therapies
Summary
President Donald Trump signed an executive order to speed up research and approval of psychedelic drugs like ibogaine for mental health conditions such as PTSD, depression, and addiction. The announcement took place at the White House with several officials and public figures present, aiming to provide new treatment options especially for veterans.Key Facts
- President Trump signed an executive order on April 18, 2026, to promote research on psychedelic drug therapies.
- The order focuses on drugs like ibogaine, which is currently a Schedule 1 controlled substance with restrictions due to potential risks and limited research.
- Psychedelic drugs are being studied for mental health issues including PTSD, depression, anxiety, and addiction.
- Officials present at the signing included Health and Human Services Secretary Robert F. Kennedy Jr., FDA Commissioner Marty Makary, Dr. Mehmet Oz, and podcaster Joe Rogan.
- Joe Rogan privately lobbied President Trump to take action on easing restrictions on these therapies.
- The order aims to help veterans who face severe mental health challenges by providing new treatment options.
- Ibogaine has serious safety concerns like heart rhythm problems and other side effects, though some evidence hints at potential benefits.
- Psilocybin, from magic mushrooms, has stronger research support and FDA recognition for treating depression but is still federally restricted.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
